Summary
Plasma pharmacokinetics and biliary and urinary excretion of the new doxorubicin analogue, epirubicin, have been studied in three patients with extrahepatic obstruction and percutaneous biliary drainage.
At variance with the reported observations concerning doxorubicin metabolism, conjugation of epirubicin and 13-dihydroepirubicin with glucuronic acid takes place, and corresponding amounts of 4'-o-β-D-glucuronyl-4'-epidoxorubicin and 4'-o-β-D-glucuronyl-13-dihydro-4'-epidoxorubicin can be found in the bile and urine.
The total amount of unaltered drug and metabolites excreted in the bile in the first 4 days after treatment accounts for the 37%, 27%, and 40% of the administered dose; urinary excretion accounts for 19%, 16%, and 26%. Biliary clearance of epiDX (32.5, 8.1 and 21.6 l/h) is higher than renal clearance (15.2, 3.3 and 9.4 l/h).
The relevance of the biliary disposition of epirubicin suggest prudent dose reduction in patients with impaired biliary drainage.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arcamone F, Penco S, Vigevani A, Redaelli S, Franchi G, Di Marco A, Casazza AM, Dasdia T, Formelli F, Necco A, Soranzo C (1975) Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. J Med Chem 18: 703–707
Bircher J, Preisig R (1981) In Vivo assessment of hepatic drug disposition. In: Jenner P, Testa B (eds) Concepts in drug metabolism, part B. Dekker, New York, pp 377–422
Caldwell J (1980) Conjugation reactions. In: Jenner P, Testa B (eds) Concepts in drug metabolism. Part A. Marcel Dekker, New York, pp 211–250
Camaggi CM, Strocchi E, Tamassia V, Martoni A, Giovannini M, Iafelice G, Canova N, Marraro D, Martini A, Pannuti F (1982) Pharmacokinetic studies of 4'epidoxorubicin in cancer patients with normal and impaired renal functions and with hepatic metastases. Cancer Treat Rep 66: 1819–1824
Camaggi CM, Strocchi E, Martoni A, Angelelli B, Comparsi R, Pannuti F (1985) Epirubicin plasma and blood pharmacokinetics after single IV bolus in advanced cancer patients. Drugs Exp Clin Res XI (4): 285–294
Cassinelli G, Configliacchi E, Penco S, Rivola G, Arcamone F, Pacciarini A, Ferrari L (1984) Separation, characterization and analysis of epirubicin (4'-Epidoxorubicin) and its metabolites from human urine. Drug Metab Dispos 12: 4–20
Dixon WJ, Brown MB (1979) BMDP-79 biomedical computer programs, P-series. University of California Press, Berkeley
Ganzina F (1979) 4'-Epidoxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev 10: 1–22
Gibaldi G, Perrier D (1982) Pharmacokinetics, 2nd edn Dekker, New York
Pannuti F, Camaggi CM, Strocchi E, Comparsi R, Angelelli B, Pacciarini MA (1986) Lowdose oral administration of 4-demethoxydaunorubicin (Idarubicin) in advanced cancer patients. A pharmacokinetics study. Cancer Chemother Pharmacol 16: 295–299
Riggs CE, Benjamin RS, Serpick AA, Bachur NR (1977) Biliary disposition of adriamycin. Clin Pharmacol Ther 22: 234–241
Weenen H, Lenkelma JP, Penders PGM, McVie JG, Ten Bokkel Huinink WW, De Planque MM, Pinedo HM (1983) Pharmacokinetics of 4'-epi-doxorubicin in man. Invest New Drugs 1: 59–64
Author information
Authors and Affiliations
Additional information
Supported in part by contract, CNR, MO85.00710.44 (Progetto Finalizzato “Oncologia”, Italian National Council of Research)
Rights and permissions
About this article
Cite this article
Camaggi, C.M., Strocchi, E., Comparsi, R. et al. Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. Cancer Chemother. Pharmacol. 18, 47–50 (1986). https://doi.org/10.1007/BF00253063
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00253063